Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Oxford BioDynamics PLC (LMQ.BE)

Compare

0.0060

-0.0005

(-7.69%)

As of 2:50:05 PM GMT+1. Market Open.

Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps

OXFORD, England, February 05, 2025--Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps.

Business Wire 26 days ago

OXBOF
Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.

OXFORD, England, July 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch® 3D genomics platform [1], announces its key-note presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, taking place on 3-6 September 2024 in Boston, MA, USA.

Business Wire 7 months ago

OXBOF
Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy

OXFORD, England, June 25, 2024--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD’s EpiSwitch® 3D genomics platform,[4] announces that it has formed a strategic consortium which has been shortlisted for the UK Government’s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium’s

Business Wire 8 months ago

OXBOF
Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers

OXFORD, England, June 04, 2024--Oxford BioDynamics Plc (AIM: OBD, the "Company"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces development of a high-accuracy, discriminating multi-cancer canine diagnostic test for veterinary medicine.

Business Wire 8 months ago

OXBOF

Performance Overview

Return	LMQ.BE	FTSE 100
YTD	-60.00%	+8.84%
1-Year	-95.95%	+15.79%
3-Year	-97.84%	+22.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oxford BioDynamics PLC (LMQ.BE)

Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps

Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.

Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy

Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers

Performance Overview